Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors

AbstractSomatostatin receptors (SSTR) are commonly expressed by neuroendocrine tumors. Expression of SSTR-2a and SSTR-5 may impact symptomatic management; however, the impact on survival is unclear. The aim of this study is to correlate SSTR-2a and SSTR-5 expression in pancreatic neuroendocrine tumors (PNETs) with survival.This study is designed to determine the prognostic significance of somatostatin receptors SSTR-2a and SSTR-5 in PNETs.This retrospective cohort study included cases of resected PNETs between 1992 and 2014. Clinical data, histopathology, expression of SSTR and Ki-67 by immunohistochemistry, and long-term survival were analyzed.A total of 99 cases were included in this study. The mean age was 57.8 years (18–87 years) and median tumor size was 25 mm (range 8–160 mm). SSTR-2a and SSTR-5 expression was scored as negative (n = 19, 19.2%; n = 75, 75.8%, respectively) and positive (n = 80, 80.1%; n = 24, 24.2%). The median follow-up was 49 months. SSTR-2a expression was associated with improved overall survival, with cumulative survival rates at 1, 3, and 5 years being 97.5%, 91.5%, and 82.9%, respectively. Univariate analysis demonstrated better survival in SSTR-2a positive patients (log rank P = 0.04). SSTR-5 expression was not associated with survival outcomes (log rank P = 0.94). Multivariate analysis showed that positive SSTR-2a expression is a stronger prognostic indicator for overall survival [Hazard Ratio (HR): 0.2, 95% Confidence interval (CI): 0.1–0.8] compared to high Ki-67 (HR: 0.8, 95% CI: 0.1–5.7).Expression of SSTR-2a is an independent positive prognostic factor for survival in PNETs.

[1]  A. Krasinskas,et al.  The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms , 2015, The American journal of surgical pathology.

[2]  A. Gill,et al.  Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas. , 2015, Human pathology.

[3]  M. Taniguchi,et al.  Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors. , 2014, World journal of gastroenterology.

[4]  R. Minter,et al.  Tumor-Associated Macrophages Are a Useful Biomarker to Predict Recurrence After Surgical Resection of Nonfunctional Pancreatic Neuroendocrine Tumors , 2014, Annals of surgery.

[5]  A. Vinik.  Advances in diagnosis and treatment of pancreatic neuroendocrine tumors. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[6]  Feng Yang,et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.

[7]  M. Saegusa,et al.  Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes , 2013, Cancer.

[8]  A. Gill,et al.  Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). , 2013, Human pathology.

[9]  Toby C. Cornish,et al.  Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate , 2013, The American journal of surgical pathology.

[10]  S. Schulz,et al.  Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors. , 2013, International journal of clinical and experimental pathology.

[11]  A. Faggiano,et al.  Epidemiology of gastroenteropancreatic neuroendocrine tumours. , 2012, Best practice & research. Clinical gastroenterology.

[12]  E. Wolin.  The expanding role of somatostatin analogs in the management of neuroendocrine tumors. , 2012, Gastrointestinal cancer research : GCR.

[13]  W. Fisher,et al.  Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5. , 2012, Molecular endocrinology.

[14]  J. Reubi,et al.  Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for In Vivo Somatostatin Receptor Targeting , 2012, The American journal of surgical pathology.

[15]  F. D. De Braud,et al.  Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. , 2010, Cancer treatment reviews.

[16]  Domenico Coppola,et al.  The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems , 2010, Pancreas.

[17]  D. Klimstra,et al.  The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement , 2010, Virchows Archiv.

[18]  William Mantovani,et al.  Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients , 2010, Modern Pathology.

[19]  R. Baldelli,et al.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives , 2010, Journal of experimental & clinical cancer research : CR.

[20]  Wei Liu,et al.  Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in mice , 2010, Journal of experimental & clinical cancer research : CR.

[21]  I. Modlin,et al.  article : somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine ( carcinoid ) tumours , 2009 .

[22]  A. Scarpa,et al.  Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas , 2008, Neuroendocrinology.

[23]  Takashi Suzuki,et al.  Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. , 2007, Anticancer research.

[24]  S. Lamberts,et al.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. , 2003, Endocrine-related cancer.

[25]  M. Papotti,et al.  Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors , 2002, Virchows Archiv.

[26]  N. Kimura,et al.  Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.